A Look at the Performance of Novartis’s Alcon

Alcon, Novartis’s (NVS) eye care business, includes surgical products and vision care products. 

Alcon reported revenue of ~$1.82 billion in the second quarter, a 7% rise including the 5% increase in its operating revenue and the 2% favorable impact of foreign exchange.

The above chart compares Alcon’s revenue trends since the first quarter of 2017. Alcon announced in September 2018 that it would be locating its future headquarters in Geneva, Switzerland, following the completion of the proposed spinoff from Novartis.

The segment’s surgical products reported an 8% rise in operating revenue in the second quarter, while its vision care products reported a 1% rise in revenue in the quarter.

The segment’s surgical sales reported revenue of ~$1.0 billion in the second quarter, a 10% rise compared to $938 million in the second quarter of 2017.

The segment’s consumables revenue rose 7% to $578 million, while its revenue from implants rose 15% to $298 million, and its revenue from the sales of equipment and other products rose 10% to $154 million in the quarter.

The vision care franchise reported revenue of ~$789 million in the second quarter, a 3% rise compared to its revenue of $769 million in the second quarter of 2017.

Revenue from contact lenses increased 5% to $478 million, while revenue from ophthalmic over-the-counter products decreased to $176 million, and revenue from contact lens care products decreased to $135 million in the quarter.

The First Trust Value Line Dividend ETF (FVD) holds 0.5% in Novartis, 0.5% in Merck & Co. (MRK), 0.5% in Sanofi (SNY), and 0.5% in Bristol-Myers Squibb (BMY).